The exciting news coming out of Israel, that a scientist has developed a groundbreaking test to categorically detect Parkinson’s disease, is giving the medical and science worlds hope for the future.
Suaad Abd-Elhadi, a PhD student at the Institute for Medical Research Israel-Canada in the Hebrew University of Jerusalem Faculty of Medicine, has developed the lipid ELISA diagnostic tool.
She won the Kaye Innovation Award for 2017 for the breakthrough invention of this highly sensitive kit that may lead to earlier detection of Parkinson’s disease, along with better tracking of the disease’s progression and a patient’s response to therapy.
Parkinson’s disease is the second most common neurodegenerative disorder in humans, after Alzheimer’s disease. It is typically characterized by changes in motor control such as tremors and shaking, but can also include non-motor symptoms, from the cognitive to the behavioral.
An estimated seven to 10 million people worldwide are living with Parkinson’s disease, with medication costing approximately $2,500 a year, and therapeutic surgery costing up to $100,000 per patient.
Making an accurate diagnosis of Parkinson’s, particularly in early stages and mild cases, is difficult, and there are currently no standard diagnostic tests other than clinical information provided by the patient and the findings of a neurological exam.
Once Parkinson’s is revealed, the disease is usually already progressing.
“Earlier diagnosis can help by seeing how a given drug affects the progress of the disease, for example,” Abd-Elhadi told Haaretz.
Read More: Israel21C